baber/WOPTO huggingface dataset:
Patent NZ-207058-A (NZ)
Title: Trip mechanism for deactivating elevator platforms
Inventor: MARTIN J C
IPC: B66B5/00
Filed: 1984-02-07
Abstract: An elevator mechanism device having first and second platforms mounted in a frame for movement relative to one another wherein a nip is formed between a lower edge of the first platform and an upper edge of the second platform as they move toward one another and wherein an electrically operated control circuit is provided for controlling the movement of the platforms relative to one another, the improvement of a flexible skirt extending below the lower edge of said first platform across the width of the nip whereby during movement of the platform to close the nip, a trip will be engaged by and deflected by any object which may project into the nip, a circuit breaker operable to de-activate the control circuit, the trip communicating between each end of the flexible skirt and the circuit breaker to activate the circuit breaker to de-activate control circuit when the trip is deflected to an extent less than that required to permit the object to be clamped between the first and second platforms.
Patent NZ-209986-A (NZ)
Title: Suction operated skin contact electrode
Inventor: LUNDBACK S
IPC: A61B5/296
Filed: 1984-10-25
Abstract: The invention relates to an electrode intended, for example, for electrocardiogram examinations, and capable of being held in position by suction. Vacuum conditions are created through a hose or tube (8), through which a measuring conductor (7) is drawn. The electrode comprises an inflexible backpiece (3), an intermediate component (2) made of an elastomeric material, and an electrode plate (1), preferably made of a silver-coated plastics. The intermediate component (2) includes a relatively inflexible sealing ring (9) which, in the operative state of the electrode, supports against the skin of a patient via a sealing lip (13) and against the opposing side of the backpiece (3). The electrode plate (1) is firmly connected to the backpiece, while the sealing ring carried by the intermediate component (2) is movable and can be readily sprung away from the backpiece (via resilient means 17). When no load is exerted on the lip-side of the ring and the ring is thus urged outwardly, a vacuum valve is closed automatically through the intermediate component (2), and is re-opened when the electrode is pressed against the surface of the skin, whereupon the electrode is held firmly by suction.
Patent NZ-215863-A (NZ)
Title: Penicillanic acid derivatives
Inventor: REED L A
IPC: C07D499/00
Filed: 1986-04-17
Abstract: Compounds having the formula: <CHEM>  wherein n is 0, 1 or 2;  X is OH or OCOR<2>m wherein R<2> is hydrogen or (C1-C4) alkyl; R is hydrogen, a radical group forming an ester hydrolyzable under physiological conditions, or an acyloxymethyl or 1-(acyloxy)ethyl radical derived from a convential beta-lactam antibiotic; and R<1> is selected from a wide range of alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclylalkyl groups  and their pharmaceutically acceptable salts. These compounds are useful as antibacterials and/or beta-lactamase inhibitors.
Patent NZ-215882-A (NZ)
Title: Aqueous anionic dispersion for fabric treatment
Inventor: HINTERMEIER K
IPC: D06M13/428
Filed: 1986-04-18
Abstract: An agent effective for oleophobizing and hydrophobizing textiles is an aqueous anionic dispersion which comprises water and (A) 5 to 25% by weight of a reaction product which contains at least one bis-(2-fluoroalkyl-ethoxy-carbonylamino)-toluene of the formula YCF2(CF2)nCH2CH2OCO  +TR  <IMAGE>    wherein n is a number from 5 to 15 and Y is -H or -F, and wherein said reaction product is prepared by reacting 2-perfluoroalkylethanol of the formula YCF2-(CF2)n-CH2CH2OH  with tolylene diisocyanate in a molar ratio of (1.8 to 2):1 in the presence of 2 to 5% by weight of N-methylpyrrolidone, relative to the perfluoroalkylethanol, (B) 1 to 14% by weight of at least one emulsifier of the formula YCF2(CF2)p-CH2CH2O-CO-NH-CH2CH2-SSO3X  wherein p is a number from 5 to 15, Y is -H or -F, and X is a monovalent cation, (C) 1 to 14% by weight of at least one nonionic emulsifier of the formula YCF2-(CF2)q-CH2CH2-(OCH2CH2)r-OH  wherein Y is -H or -F, q is a number from 5 to 15, r is a number from 0 to 10, and (D) 5 to 30% by weight of a solvent or solvent mixture, with the proviso that the sum of the amounts of components (B) and (C) is 2 to 15%.
Patent NZ-217428-A (NZ)
Title: Self-engaging separable fastener and production thereof
Inventor: PROVOST G A
IPC: A44B18/00
Filed: 1986-09-02
Abstract: A self-engaging separable fastener is disclosed which comprises a base member (16) of woven separable fastener material having at least two adjacent mating fastener sections (12,14). At least one section (12) is defined by a plurality of loops (18) upstanding from the base member (16), and the other section (14) is defined by a plurality of hooks (20') upstanding from the base member (16). The loops (18) are formed of respective generally parallel rows of multifilament yarns interwoven into their respective base section so as to repeat the same loop direction and construction every predetermined number of picks and the hooks (20') are cut from respective generally parallel rows of loops (20) of monofilament yarns interwoven into their respective base section so as to repeat their loop direction and construction every pre­determined number of picks, which latter number of picks is greater than the number of picks in which the direction of the multifilament loops (18) is repeated. The density of the monofilament hooks (20') is less than the density of the multifilament loops (18) such that the sections of fastener material may be placed in face-to-face engagement by folding one section over the other and pressing the surfaces together and separated by peeling forces normal to the interfacial plane of engagement. Preferably, the loops (18) repeat themselves every four picks and the hooks (20') repeat themselves every eight picks.
Patent NZ-217721-A (NZ)
Title: Process for n-alkylation of dihydrolysergic acid
Inventor: MARZONI G P
IPC: A61K31/48
Filed: 1986-09-29
Abstract: The present invention provides a process for preparingwherein R' is C<sub>3</sub>-C<sub>e</sub> alkyl, -CH<sub>2</sub>C<sub>2</sub>-C<sub>4</sub> alkenyl, propargyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl or C<sub>1</sub>-C<sub>6</sub> alkyl substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl; which comprises: reacting a compound of Formula (II):with a substituted benzenesulfonate of Formula III):wherein R' is as defined above and R<sup>2</sup> is hydrogen, bromo, methyl or nitro, in the presence of a base.
Patent NZ-223312-A (NZ)
Title: Precursor protein of amyloid plaque protein and dna encoding it
Inventor: MULLER-HILL BENNO
IPC: C12Q1/68
Filed: 1988-01-27
Abstract: The precursor protein of "amyloid plaque core" (APC) polypeptide, fragments of the precursor protein and the diagnostic use of the precursor protein or the fragments are described. The DNA coding for the precursor protein, fragments of this DNA and the diagnostic use of the DNA or the fragments is additionally described.
Patent NZ-229372-A (NZ)
Title: Controlled release, solid, oral dosage form comprising 3-alkylaxanthine, a polymer and a wax
Inventor: HEAFIELD JOANNE
IPC: A61K9/22
Filed: 1989-05-31
Abstract: A controlled release, solid, oral dosage form containing a 3-alkylxanthine, preferably theophylline, at least one hydrophilic or hydrophobic polymer, at least one wax having a melting point between 25 DEG  and 90 DEG C and between 3% and 10% (by weight) water. Preferably the dosage form is a tablet and the water content is between 4% and 9% (by weight). The amount of water present in the dosage form determines the rate of release of the 3-alkylxanthine.
Patent NZ-232426-A (NZ)
Title: 5-methoxyindol-2-yl methylamine derivatives and pharmaceutical compositions
Inventor: ALVAREZ ELDIBERTO FERNANDEZ
IPC: A61P25/04
Filed: 1990-02-08
Abstract: Compounds of structure (1): <CHEM>  and pharmaceutically acceptable salts are described, wherein  R is hydrogen or C1-4alkyl, R min  is hydrogen, C1-4alkyl, or a C1-4alkyl group substituted by an alkyne or allene group provided that R min  is not methyl when R and R sec  are both hydrogen, and R sec  is hydrogen or a C1-4alkyl group substituted by an alkyne or allene group. These compounds have anti-depressant activity. Processes for the preparation of the compounds, pharmaceutical compositions and methods of use, are described.
Patent NZ-236253-A (NZ)
Title: Iontophoretic administration of pharmacological agents to non-human animals in conjunction with a dermal penetration enhancer
Inventor: FRANCOEUR MICHAEL LEE
IPC: A61K31/40
Filed: 1990-11-28
Abstract: Transdermal flux enhancers such as oleic acid and 1-dodecylazacycloheptan-2-one are used in combination with iontophoresis in the topical administration of pharmaceutical agents.
Patent NZ-238734-A (NZ)
Title: Monoclonal antibodies to sulphonylurea herbicides.
Inventor: SCHLAEPPI JEAN-MARC
IPC: C07K16/00
Filed: 1991-06-27
Abstract: The present invention relates to monoclonal antibodies which are distinguished by high selectivity and affinity for triasulfuron and which are therefore outstandingly suitable for use in an immunoassay for the rapid and efficient detection of triasulfuron. Another aspect of the present invention relates to hybridoma cell lines which produce said monoclonal antibodies and to immunological methods for detecting triasulfuron in samples of soil, water or air using said monoclonal antibodies and to the assay kits which can be used within the scope of these detection methods.
Patent NZ-246059-A (NZ)
Title: Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
Inventor: FISHLEIGH ROBERT VINCENT
IPC: C07K16/00
Filed: 1992-12-03
Abstract: Synthetic polypeptides having at least one antigenic site of a prior protein, methods for their use and manufacture, antibodies raised against such polypeptides and diagnostic kits containing these polypeptides or antibodies.
Patent NZ-246434-A (NZ)
Title: Imidazoylalkyl substituted by a six membered nitrogen containing heterocycle; pharmaceutical compositions and preparatory methods
Inventor: SHIH NENG-YANG
IPC: A61P25/28
Filed: 1992-12-16
Abstract: Disclosed is a compound of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a compound of formula (1.0). Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma), i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of formula (1.0) to a patient in need of such treatment.
Patent NZ-253524-A (NZ)
Title: Sulphur-containing phosphonate derivatives and medicaments (for treating abnormal calcium and phosphate metabolism)
Inventor: KAAS SUSAN MARY
IPC: C07F/
Filed: 1993-05-26
Abstract: Compounds of the formula   <IMAGE>   where m and n are integers 0 to 10 and m+n equals 0 to 10, (a) X is O or S (b) Z is a covalent bond; a monocyclic or polycyclic carbocycle ring moiety; or a monocyclic or polycyclic heterocyclic ring moiety containing one or more heteroatoms selected from O, S, or N; (c) Q is covalent bond; O; or S; (d) R is COOH, SO3H, PO3H2, or P(O)(OH)R4, wherein R4 is C1-C8 alkyl; (e) R1, R2 and R5 are as defined in the claims. are useful in the treatment of calcium and phosphate elated disorders, such as arthritis and the like.
Patent NZ-273673-A (NZ)
Title: Concrete mixer, method and apparatus in which the mixing chamber has a dry mixing chamber portion and a wet mixing chamber portion leading to a lower discharge portion
Inventor: HAY ALLAN MCLEOD
IPC: B01F25/74
Filed: 1994-10-03
Abstract: PCT No. PCT/GB94/02141 Sec. 371 Date Mar. 14, 1997 Sec. 102(e) Date Mar. 14, 1997 PCT Filed Oct. 3, 1994 PCT Pub. No. WO95/09690 PCT Pub. Date Apr. 13, 1995A materials mixer, suitable for mixing concrete, comprises a generally cylindrical housing (10) which houses a mixing chamber (15) consisting of an upper, dry mixing chamber portion (2), a central, wet mixing chamber portion (3) and a lower, discharge chamber portion (4). The materials mixer has an entrance (20) for materials to be mixed and an exit (25) for the complete mixture, between which are a plurality of rotating members (30, 40, 50, 60) which disrupt the flow of materials through the chamber (15) causing mixing of the materials. The shape of the mixing chamber is defined by a plurality of baffle plates (11, 12, 16) which help determine the path of the materials though the chamber.
Patent NZ-314142-A (NZ)
Title: Tote return system, typically for airport luggage, with elevating, conveying and transfer devices
Inventor: KIERPAUL CHESTER FELIX
IPC: B65G47/57
Filed: 1997-01-29
Abstract: A tote conveyor system for transporting totes from an end-of-use point to the point-of-use. The conveyor system comprising a combination of conveyors including a vertical conveyor and a substantial horizontal conveyor with a means to transferring totes between the two different systems.
Patent NZ-321443-A (NZ)
Title: Stable biotinylated biomolecule composition and methods
Inventor: BURTON STEVEN J
IPC: C07K17/06
Filed: 1996-10-24
Abstract: ompositions and methods for biotinylated biomolecules, such as enzymes, are disclosed. The compositions include a biotinylated biomolecule, a biomolecule protectant, a buffer, a bulking agent selected from one or more water soluble, nonionic polymers and preferably a terminal sterilization protectant.  The compositions can be utilized either as aqueous solutions or preferably in dried form, e.g., as a lyophilized powder cake.  They have applicability in any case wherein avidin/biotin technology is used, and are particularly important as compositions containing a thrombin-like enzyme.  The preparation of a fibrin monomer and fibrin monomer-based fibrin sealants are an example wherein avidin/biotin technology is used and methods of providing such monomers are also disclosed.
Patent NZ-333632-A (NZ)
Title: Use of a neuroactive peptide having at least one of the biological activities of angiotensin IV or a biologically active analogue
Inventor: MENDELSOHN FEDERICK A O
IPC: A61K38/00
Filed: 1997-07-09
Abstract: The use of a neuroactive peptides or analogues thereof, having at least one of the biological activities of angiotensin IV, in the manufacture of a pharmaceutical composition for modulating neuronal activity. The peptide comprises the sequence Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe and the biological activities demonstrated by the peptide are selected from the group consisting of modifying learning, modifying behaviour, vasoactive effects, dilation of cerebral arteries, renal blood flow, increase in stereotype behaviour, facilitating memory retrieval, neurite modelling and alleviation of the effects of spinal cord injury. Also disclosed is a method of screening for putative agonists or antagonists of the effect of LVV-haemorphin-7 on neuronal activity.
Patent NZ-334739-A (NZ)
Title: Method of screening animals resistant or susceptible to diseases caused by intracellular parasites by analysing the bovine Nramp1 DNA sequence
Inventor: TEMPLETON JOE W
IPC: C12Q1/68
Filed: 1997-09-19
Abstract: The method for screening animals that are susceptible to diseases associated with intracellular parasites comprises analyzing an animal's genetic material for the presence of one or more specific genetic sequences associated with bovine Nramp1 which sequence associates with susceptible of an animal to disease caused by intracellular parasites and is selected from the groups of SEQ ID Nos: 12, 13, 14 and 40 as depicted in the specification. The method for screening animals that are resistant to diseases associated with intracellular parasites comprises analyzing an animal's genetic material for the presence of one or more specific genetic sequences associated with bovine Nramp1 which sequence associates with resistance of an animal to disease caused by intracellular parasites and is selected from the groups of SEQ ID Nos: 11, 15, 29 and 31 as depicted in the specification.
Patent NZ-500546-A (NZ)
Title: Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV)
Inventor: SAMULSKI RICHARD J
IPC: C12N7/01
Filed: 1998-04-14
Abstract: Methods and compositions for increasing the production of high titre stocks of recombinant adeno-associated AAV (rAAV) through regulation of expression of the AAV REP and CAP proteins are described. The methods and compositions are based on the observation that the low level expression of the AAV REP protein increases the production of AAV viral capsid protein and efficiency of packaging resulting in production of higher titre recombinant viral stocks. Also described are rAAV vectors that direct the expression of AAV REP and CAP proteins and the use of such vectors for the production of stable cell lines capable of generating high titre rAAV vectors. Methods for regulating the expression of the AAV REP gene at the transcriptional and post-translational level are also provided.
Patent NZ-501596-A (NZ)
Title: Probes to detect and identify common bacterial pathogens and antibiotic resistance genes
Inventor: BERGERON MICHEL G
IPC: C07K14/31
Filed: 1995-09-12
Abstract: The specification describes a method for the detection of a target bacterial species suspected to be present in a sample, characterized in: a) contacting the nucleic acids of the target bacterial species with at least one amplification primer pair, i) the primer pair being derived from a bacterial DNA fragment that is specific for a given target bacterial species and that is ubiquitous for the strains of the given target bacterial species, ii) when required, the primer pair of i) being pooled with another primer pair, to reach an ubiquity of 100%. The other primer pair is derived from another bacterial DNA fragment that is specific and ubiquitous for the given target bacterial species, iii) the amplification primer pairs of i) and ii) being specific and ubiquitous for the given target bacterial species, iv) all amplification primers are selected to have a given amplification annealing temperature, for hybridization with the nucleic acids of the target bacterial species.  The given amplification annealing temperature allowing for multiplex amplification; b) allowing amplification to proceed under given amplification conditions which include that given annealing temperature, and c) detecting the presence or amount of a given amplified sequence as an indication of the presence or amount of a given species. The bacterial species is selected from Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphyloccus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, and group A Streptocci producing exotoxin A gene spe A Addition to 501596
Patent NZ-502398-A (NZ)
Title: Preparation of recombinant influenza A virus M2 constructs and vaccines
Inventor: FRACE A MICHAEL
IPC: C07K19/00
Filed: 1998-08-06
Abstract: A method of increasing the recombinant expression and solubility of influenza A virus M2 polypeptide comprising nucleic acids encoding a modified M2 protein of influenza A virus in which transmembrane and other hydrophobic domains have been deleted. Also, provided are purified polypeptides encoded by the nucleic acids, which polypeptides are immunogenic and are less hydrophobic than full-length M2. Also, provided are vaccines comprising variants of M2 expressed in prokaryotic hosts. Further provided are methods of preventing influenza A infections using vaccines comprised of variants of M2. Also provided are antibodies raised against the variants of M2, and use of such antibodies in diagnosis and treatment of influenza A infections.
Patent NZ-506739-A (NZ)
Title: Container collapsible to lay flat condition, with extension of wall being connected to adjacent wall by section having vertical and diagonal fold lines
Inventor: COE ROBERT WILLIAM
IPC: B65D5/36
Filed: 2000-09-04
Abstract: The container is shown in a partially folded state. Adhesive is applied at 19,20,21. After folding about transverse fold lines a "lie flat" collapsible container is obtained. This is erected by lifting out side walls of base and lid. The diagonal fold lines shown extend from a base corner, only partially to the edge of the flaps shown.
Patent NZ-508925-A (NZ)
Title: Coated sodium percarbonate particles comprising a sodium percarbonate core and a coating layer substantially free from sulphate, borate and magnesium compounds, process for their preparation
Inventor: JAMES ALUN P
IPC: C11D3/08
Filed: 1999-06-04
Abstract: Coated sodium percarbonate particles containing a sodium percarbonate core and a coating layer substantially free from sulphate, borate and magnesium compounds. The coating layer comprises at least 30% and at most 70% w/w of an alkali metal carbonate and at least 25% and at most 70% w/w of an alkali metal silicate. The coating layer is obtained by using the alkali metal carbonate and silicate in the form of a coating solution to obtain a uniform dispersion of the alkali metal carbonate and the alkali metal silicate in the coating layer. The particles are prepared by mixing the alkali metal carbonate solution and the alkali metal silicate solution with the uncoated sodium percarbonate particles in a mixer operated at a temperature from room temperature to 50oC. This distributes the coating solution on the surface of the particles to obtain wet coated particles. The wet coated particles are removed form the mixer and dried in a fluid bed dryer using a stream of hot air of a temperature from 50 to 90oC to obtain dry coated particles. The coated sodium percarbonate particles may be used as an active bleach constituent and either a zeolitic or non-zeolitic builder in detergent compositions.
Patent NZ-509276-A (NZ)
Title: Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects
Inventor: CAVAZZA CLAUDIO
IPC: C12N1/16
Filed: 2000-04-07
Abstract: A composition for increasing the absorption of glutathione and for synergizing its effects. This composition may take the form of a dietary supplement, dietetic support or of an actual medicine and comprises: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; (b) glutathione or a glutathione-containing yeast; (c) a glutathione-free yeast if the component (b) consists of glutathione. Methods of making the composition are also disclosed.
Patent NZ-509452-A (NZ)
Title: Use of a cyclic siloxane composition for drycleaning by total immersion of articles in a dry cleaning machine
Inventor: BERNDT WOLD-DIETER R
IPC: C11D11/00
Filed: 1999-07-14
Abstract: A dry cleaning system and method comprising specially designedmachinery used in conjunction with a cyclic siloxane solvent is described.  The method comprises the steps of loading articles into a cleaning basket; agitating the articles and the siloxane composition in which they are immersed; removing most of the siloxane composition; centrifuging the articles; subjecting the articles to a partial vacuum pressure and elevated temperature; and removing the articles from the basket after cooling and returning the pressure to ambient.
Patent NZ-510233-A (NZ)
Title: Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol for intraspinal administration
Inventor: LEINO TIINA
IPC: A61K31/416
Filed: 1999-09-27
Abstract: 3-(1H-imidazol-4-ylmethyl)indan-5-ol it enantiomer or pharmaceutically acceptable ester or salt thereof is used for intraspinal administration to treat intraoperative pain, postoperative pain, obstetric pain, chronic pain or spastic paraplegia.